- Home
- ACRV vs BNR Comparison
ACRV vs BNR Comparison
Compare ACRV & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- BNR
- Stock Information
- Founded
- ACRV 2018
- BNR 2014
- Country
- ACRV United States
- BNR China
- Employees
- ACRV N/A
- BNR N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- BNR Medical Specialities
- Sector
- ACRV Health Care
- BNR Health Care
- Exchange
- ACRV Nasdaq
- BNR Nasdaq
- Market Cap
- ACRV 36.1M
- BNR 29.1M
- IPO Year
- ACRV 2022
- BNR 2020
- Fundamental
- Price
- ACRV $1.09
- BNR $3.09
- Analyst Decision
- ACRV Buy
- BNR
- Analyst Count
- ACRV 7
- BNR 0
- Target Price
- ACRV $17.60
- BNR N/A
- AVG Volume (30 Days)
- ACRV 728.6K
- BNR 68.0K
- Earning Date
- ACRV 05-14-2025
- BNR 06-10-2025
- Dividend Yield
- ACRV N/A
- BNR N/A
- EPS Growth
- ACRV N/A
- BNR N/A
- EPS
- ACRV N/A
- BNR N/A
- Revenue
- ACRV N/A
- BNR $70,669,261.00
- Revenue This Year
- ACRV N/A
- BNR $136.32
- Revenue Next Year
- ACRV N/A
- BNR N/A
- P/E Ratio
- ACRV N/A
- BNR N/A
- Revenue Growth
- ACRV N/A
- BNR N/A
- 52 Week Low
- ACRV $1.05
- BNR $2.18
- 52 Week High
- ACRV $10.16
- BNR $7.90
- Technical
- Relative Strength Index (RSI)
- ACRV 34.87
- BNR 51.73
- Support Level
- ACRV $1.06
- BNR $2.99
- Resistance Level
- ACRV $1.19
- BNR $3.45
- Average True Range (ATR)
- ACRV 0.09
- BNR 0.33
- MACD
- ACRV 0.05
- BNR 0.10
- Stochastic Oscillator
- ACRV 21.57
- BNR 70.59
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.